Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data

Black patients chronically infected with genotype 1 hepatitis C virus (HCV) have historically had lower rates of response to interferon‐based treatment than patients of other races. In the phase 3 ION program, the single‐tablet regimen of the NS5A inhibitor ledipasvir and NS5B nucleotide polymerase...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilder, Julius M., Jeffers, Lennox J., Ravendhran, Natarajan, Shiffman, Mitchell L., Poulos, John, Sulkowski, Mark S., Gitlin, Norman, Workowski, Kimberly, Zhu, Yanni, Yang, Jenny C., Pang, Phillip S., McHutchison, John G., Muir, Andrew J., Howell, Charles, Kowdley, Kris, Afdhal, Nezam, Reddy, K. Rajender
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Viral Hepatitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738375/
https://www.ncbi.nlm.nih.gov/pubmed/26547499
http://dx.doi.org/10.1002/hep.28334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738375/
https://www.ncbi.nlm.nih.gov/pubmed/26547499
http://dx.doi.org/10.1002/hep.28334

Ejemplares similares